Shares of IBM climbed 3.7% to $250.86 ahead of the company's third-quarter 2026 earnings report, due after today's close — capping a 10% run-up over the past five trading sessions as investors bet that a rebound in software revenue and converting delayed enterprise deals will show up in the numbers. IBM Rallies 10% in Five Days Before Earnings: Is the Market Pricing In a Deal Recovery That May Not Have Fully Arrived?
Shares surged 3.7% to $250.86 as investors placed aggressive bets ahead of IBM's third-quarter report, due after today's close. The stock has now climbed roughly 10% in five sessions, its sharpest pre-earnings rally of the year — driven by hopes that delayed enterprise deals have finally converted into booked revenue. The question: has the market already priced in good news that IBM may only partially deliver?
The Q2 Debacle Set a Low Bar — and Now Investors Are Betting on a Bounce
IBM shares plummeted 25% in July after the company released preliminary Q2 results that fell short of expectations.
Revenues rose just 1.1% to $17.16 billion but missed consensus by 0.9%, as delayed large capital-expenditure-sensitive software transactions and weaker mainframe revenues dragged results.
The shortfall prompted a full-year revenue growth outlook cut to 4%–5% from the prior 5%+. That reset means Wall Street's expectations for Q3 are modest: analysts expect earnings of $2.86 per share (up 8% year-over-year) on revenue of $16.82 billion, up from $16.33 billion.
The Slipped-Deal Math Still Doesn't Fully Add Up
CEO Arvind Krishna told analysts roughly a third of the slipped deals had already closed in early Q3, calling it "deferral, not destruction." But UBS, which rates IBM Neutral, said the company had recaptured less than half of those slipped deals , estimating Q3 revenue at $16.68 billion — below consensus. If conversion fell short, management's revised software growth target of 6%–8% could come under pressure again.
The Stock Has Outrun Most Analyst Targets
At $250.86, IBM now trades above Evercore ISI's $250 Outperform target and well past Morgan Stanley's recently raised $238 Equal-Weight target.
The average analyst price target sits at $259.76 , leaving just 3.5% upside — thin reward if results merely meet expectations. Options markets are pricing a ±7.16% post-earnings swing, well above the four-quarter average of 3.67% , signaling traders see a binary outcome tonight.
Dividend Holders Need Cash Flow Confirmation
IBM yields 2.64% with a 46% payout ratio , making free-cash-flow delivery critical. First-half free cash flow held flat at $4.8 billion, and management kept its target of roughly $1 billion in year-over-year improvement. Any downgrade to that pledge would rattle income-focused shareholders who have stayed through the sell-off.
The bottom line: IBM's rally reflects hope, not proof. Tonight's numbers — particularly software deal conversion and cash-flow guidance — will determine whether the stock's recent surge was prescient or premature.